Zhi-wei Zhou
    Title Director and Professor

    Professor Zhi-wei Zhou is a Professor and the Director of the Department of Gastric Surgery at Sun Yat-sen University Cancer Center (SYSUCC). Professor Zhou obtained his Bachelor in Medicine in 1984 and Ph.D. in 2007 at Sun Yat-sen University of Medical Sciences, P. R. China. He started his residency training at the China-Japan Friendship Hospital in Beijing in 1984, which he continued at  Sun Yat-sen University Cancer Center in the Department of Abdominal Surgery from 1986 to 1991. He was promoted to Attending Surgeon, Associate Professor, and Professor in 1991, 1998, and 2004, respectively.

    He has extensive experience and expertise in the diagnosis and treatment of abdominal malignancies (including gastric cancer, colorectal cancer, pancreatic cancer, retroperitoneal tumors, neuroendocrine tumors, and gastrointestinal tumors), soft tissue malignancies, and melanoma for over 30 years. He also specializes in the surgical treatment of gastric cancer.

    Professor Zhou was appointed as the Director of the Department of Gastric and Pancreatic Surgery in SYSUCC in 2009 and still holds this position. He also has many academic posts such as the President of Gastric Cancer Specialty Committee of the Guangdong Provincial Anti-cancer Association (2013-2017), the vice-director of the Chinese Society of Clinical Oncology (CSCO; 2017-2021), and more.

    His current focus is to improve the early diagnosis and multidisciplinary treatments of gastric cancer. He has mastered open, laparoscopic, and robotic surgeries for gastric cancer. Regarding research work, he focuses on the neoadjuvant chemotherapy, chemoradiation, and molecular typing of gastric cancer. Professor Zhou has published 3 editorial books and more than 160 research papers.
    Research Interest(s)

    (1) Neoadjuvant chemotherapy for advanced gastric cancer: Conduct both basic and clinical research (including prospective randomized controlled clinical trials) on neoadjuvant chemotherapy for advanced gastric cancer, to improve the understanding of the indications and effective regimens of neoadjuvant chemotherapy for advanced gastric cancer.

    (2) Chemoradiation for locally advanced gastric cancer: Conduct both basic and clinical research on the chemoradiation for locally advanced gastric cancer.

    (3) Translational research on molecular typing of gastric cancer: Explore the molecular types of gastric cancer using gene chips, tissue microarray, RNA sequencing technology, and more, to identify more accurate methods for predicting the prognosis and evaluate the treatment response, including sensitivity to chemotherapy and/or radiotherapy, of gastric cancer patients.


    Doctor of Philosophy (Ph.D.) in Surgical Oncology from the Sun Yat-sen University (Guangzhou, P. R. China), 2007.

    Post Graduate Training in General Surgery, Royal Adelaide Hospital (Adelaide, Australia), 2003.

    Master in Medicine from the Sun Yat-sen University of Medical Sciences (Guangzhou, P. R. China), 1999.

    Bachelor of Medicine from the Sun Yat-sen University of Medical Sciences (Guangzhou, P. R. China), 1984.


    Selected publications
    1. Wu T, Wang CH, Wang W, Liu LL, Yun JP, Zhou ZW. Association of preoperative and postoperative CA72-4 with gastric cancer outcome. J Surg Oncol. 2021;123(8):1699-1707. 

    2. Wang W, Peng Y, Feng X, Zhao Y, Seeruttun SR, Zhang J, Cheng Z, Li Y, Liu Z, Zhou Z. Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. JAMA Netw Open. 2021;4(8):e2121143. 

    3. Seeruttun SR, Xu L, Wang F, Yi X, Fang C, Liu Z, Wang W, Zhou Z. A homogenized approach to classify advanced gastric cancer patients with limited and adequate number of pathologically examined lymph nodes. Cancer Commun (Lond). 2019;39(1):32. 

    4. Nie RC, Chen FP, Yuan SQ, Luo YS, Chen S, Chen YM, Chen XJ, Chen YB, Li YF, Zhou ZW. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. Eur J Cancer. 2019;106:1-11. 

    5. Liu X, Wu Z, Lin E, Li W, Chen Y, Sun X, Zhou Z. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clin Nutr. 2019;38(4):1853-

    6. Liang Y, Hou T, Que Y, Zhao B, Xiao W, Zhang X, Zhou Z. Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection. Clin Orthop Relat Res. Published online April 27, 2019. 

    7. Wang W, Sun Z, Deng JY, Qi XL, Feng XY, Fang C, Ma XH, Wang ZN, Liang H, Xu HM, Zhou ZW. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun (Lond). 2018;38(1):23. 

    8. Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, Chen M, Chen Y, Li Y, Li S, Chen J, Zhou Z. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 2017;117(10):1544-1550. 

    9. Li B, Li Y, Wang W, Qiu H, Seeruttun SR, Fang C, Chen Y, Liang Y, Li W, Chen Y, Sun X, Guan Y, Zhan Y, Zhou Z. Incorporation of N0 Stage with Insufficient Numbers of Lymph Nodes into N1 Stage  in the Seventh Edition of the TNM Classification Improves Prediction of Prognosis in Gastric Cancer: Results of a Single-Institution Study of 1258 Chinese Patients. Ann Surg Oncol. 2016;23(1):142-148. 

    10. Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, Zhan Y, Li W, Chen Y, Sun X, Xu D, Li Y, Huang C, Zhou Z. Time trends of clinicopathologic features and surgical treatment for gastric cancer: Results from 2 high-volume institutions in southern China. Surgery. 2015;158(6):1590-1597.

    Updated November 2021

    Chen Yingbo
    Title Deputy Director, Chief physician and advisor of master’s degree students

    Prof. Chen has been engaged in medical treatment, scientific research and teaching in the Department of Abdominal Surgery at Sun Yat-sen University Cancer Center since 1992. Through the 20 years of medical practices, he has mastered the fundamental theories of oncology and basic surgical techniques and accumulated rich clinical experience in diagnosis and treatment of gastrointestinal tumor. Especially he has been well experienced in lymph node dissection for various radical surgeries of gastric cancer, the digestive tract reconstruction after radical full-stomach & proximal gastrectomy for gastric carcinoma as well as laparoscopic D2 radical gastrectomy for gastric carcinoma.

    Work experience
    1992-1997: Resident physician, Department of Abdominal Surgery at Sun Yat-sen University Cancer Center;

    1997-2004: Attending physician, Department of Abdominal Surgery at Sun Yat-sen University Cancer Center;

    2004-2011: Associate chief physician, Department of Abdominal Surgery at Sun Yat-sen University Cancer Center;

    2011-present: Chief physician, Department of Gastric and Pancreatic Surgery at Sun Yat-sen University Cancer Center.

    Research Interest(s)

    1986-1992: Undergraduate, Department of Medicine at Sun Yat-sen University of Medical Sciences;

    1996-1999: Master’s degree student of Oncology at Sun Yat-sen University of Medical Sciences;

    2010: Advanced studies in Melanoma Institute Australia, Sydney.


    1. Comparison of transthoracic and transabdominal surgical approaches for the treatment of adenocarcinoma of the cardia,Chinese journal of cancer,2010,29(8)

    2.No Survival Benefit From Postoperative Adjuvant Chemotherapy After D2 Radical Resection for the Patients With Stage II Gastric Cancer, American Journal of  Clinical Oncology,2011,

    3.Mast cells in the adjacent normal colon mucosa rather than those in the invasive margin are related to the progression of colon cancer ,Chinese Journal of Cancer Research,2011,23(4)

    4.Decreased expression of Beclin 1 correlates with a metastatic phenotypic feature and adverse prognosis of gastric carcinoma, Journal of Surgical Oncology, 2011

    5. Serosa-penetration in human T4aN0M0 gastric carcinoma correlates with worse prognosis after D2 gastrectomy,Chinese Medical Journal,2012

    6. Eficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical  total gastrectomy, Oncology Letters,2012

    Sun Xiao-Wei
    Title Associate Chief Physician
    Dr. Xiao-Wei Sun is associate senior doctor of gastric & pancreatic carcinoma. Dr. Sun obtained his Bachelor in Medicine and Master Degree in Oncology at Sun Yat-sen University of Medical Sciences, P. R. China in 1991 and 2002, respectively. As a clinical surgeon, He is responsible for abdominal cancer, such as stomach cancer, pancreatic cancer, colorectal cancer and soft tissue carcinoma. His main work is operation, outpatient service, research and teaching. Dr. Sun has published more than 20 research papers and participated in 3 monographs. He also get research funds 5, and cultivated 2 graduate students.
    Research Interest(s)

    Comprehensive treatment of advanced gastric cancer and clinical and basic study on the gastrointestinal stromal tumors


    1999.9-2002.7 Sun Yat-Sen University and Cancer Center

    Degree: Masters

    Clinical Oncology Tutor: Zhan You Qing

    Major in investigating synthesis therapy for abdominal carcinoma.

    Learn basic theory, knowledge and laboratorial skill of Medicine, receive training related to scientific research etc.

    Curricular: Clinical Oncology, Pathology, Anatomy, Statistics, English, Literature Searches, Computer and so on.



    1. Comparison of the 6th and 7th Editions of the UICC TNM Staging System for Gastric Cancer: Results of a Chinese Single-Institution Study of 1,503 Patients. Ann Surg Oncol, 2011,18:1060-1067.

    2. Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer. 2010 Nov; 29(11):923-303. Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma. World J Gastroenterol. 2010 December 21; 16(47): 6026–6034.

    Last updated on: 2011


    Liang Yao
    Title Associate Chief Physician, Master's Supervisor

    Dr. Liang is an Associate Chief Physician in the Department of Gastric Surgery at SYSUCC. He specializes in gastric cancer and soft tissue sarcoma. He graduated from Eight-year program of clinical medicine of Xiangya Medical College and obtained M.D. degree in 2013. He serves as a Committee member in multiple academic associations (e.g. Chinese Society of Clinical Oncology, Guangdong Medical Association). He won “the championship of the Case Speech Contest in China (2019 CSCO)”. Dr.Liang has undertaken different research grants including the Youth Program of National Natural Science Foundation of China. He has published more than 10 SCI papers as first author or corresponding author.

    Research Interest(s)

    Clinical Research: 1) Diagnosis and Treatment of early and advanced gastric cancer; 2) Laparoscopic Surgery of gastric cancer.

    Basic and Translational Research: 1) Mechanism of the growth and metastasis of soft tissue sarcoma and melanoma; 2) Targeted therapy of soft tissue sarcoma.


    Education 2005-2013
    M.D. Eight-year Program of Clinical Medicine, Xiangya Medical College, Central South University

    1. The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma, European Journal of Surgical Oncology. Tao Hou, Tianhui Guo, Runcong Nie, Dongchun Hong, Zhiwei Zhou, Xing Zhang, Yao Liang. European Journal of Surgical Oncology 2020

    2. Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection. Liang Y, Hou T, Que Y, Zhao B, Xiao W, Zhang X, Zhou Z. Clin Orthop Relat Res 2019

    3. LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. Que Y, Fang Z, Guan Y, Xiao W, Xu B, Zhao J, Chen H, Zhang X, Zeng M, Liang Y, Zhang X. Cancer Biol Med 2019

    4. Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients. Xiao W, Liang Y, Que Y, Li J, Peng R, Xu B, Wen X, Zhao J, Guan Y, Zhang X. J Cancer 2019

    5. Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma. Liang Y, Wang W, Que Y, Guan Y, Xiao W, Fang C, Zhang X, Zhou Z. BMC cancer 2018

    6. Combined Use of the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as a Prognostic Predictor in Patients with Operable Soft Tissue Sarcoma. Liang Y, Wang W, Li J, Guan Y, Que Y, Xiao W, Zhang X, Zhou Z. Journal of Cancer 2018

    7. Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis. Que Y, Liang Y, Zhao J, Ding Y, Peng R, Guan Y, Zhang X. Cancer Manag Res 2018

    8. Prognostic value of combined preoperative prognostic nutritional index and body mass index in HCC after hepatectomy. Ji F, Liang Y, Fu S, Chen D, Cai X, Li S, Peng B, Liang L, Hua Y. HPB 2017

    9. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). Ji F, Liang Y, Fu SJ, Guo ZY, Shu M, Shen SL, Li SQ, Peng BG, Liang LJ, Hua YP. BMC cancer 2016

    10. Research progress of Epstein-Barr virus-associated gastric carcinoma Liang Y, Zhou ZW. Zhonghua Wei Chang Wai Ke Za Zhi 2016

    Updated June 2020

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.